Long-acting TB treatment option for people living with HIV
Official title: TB LATITUDE (Long-Acting Treatment Innovation for TUberculosis Drug Effectiveness)
Funded at Global Alliance for Tb Drug Development · NIH-11302545 · Data updated 2026-11-12
A new long-acting injectable TB regimen is being developed to shorten treatment and help people living with HIV who have TB.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Global Alliance for Tb Drug Development NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 7, 2026 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $802,418 |
| NIH project number | 1R61AI197034-01 |
| Project ID | NIH-11302545 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who have active TB (drug-sensitive or drug-resistant) and may benefit from shorter, injectable TB regimens.
✕Less likely to help
This early-stage project does not yet involve patient participation or direct enrollment in a trial.
What this research studies
This project aims to create a long-acting injectable treatment for active TB that could reduce the usual six-month course to two months or less. Researchers will develop formulations for four TB drugs and test their stability and release in the lab. If successful, this could lead to a simpler, less burdensome treatment option for patients with TB and HIV. The work focuses on making injectable medicines that patients could take less frequently while still effectively curing TB.
Why it matters
Potential benefit: If successful, patients could complete TB treatment faster with fewer daily doses, improving adherence and outcomes.
How similar studies have gone: LAI approaches for infectious diseases show potential, but this project is at the formulation development stage and results are not yet proven in TB.
Where this research is happening
-
Global Alliance for Tb Drug Development
New York, United States Active
Researchers
- Principal investigator: Sun, Eugene — Global Alliance for Tb Drug Development
- Study coordinator: Sun, Eugene
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.